What is the level of liabilities of Immutep this year?
Immutep has a debt balance of 10.98 M AUD this year.
Immutep Liabilities 2024
Immutep Liabilities
10.98 M AUD
Ticker
IMM.AX
ISIN
AU000000IMM6
WKN
A2H81H
In 2024, Immutep's total liabilities amounted to 10.98 M AUD, a 35.68% difference from the 8.09 M AUD total liabilities in the previous year.
Immutep Aktienanalyse
What does Immutep do?
Immutep Ltd is an Australian biotechnology company specializing in the development of immunotherapies for the treatment of cancer and autoimmune diseases. The company was founded in 2001 and is headquartered in Sydney, Australia. The history of Immutep began with the discovery of a new type of T-cell receptor, known as lymphocyte activation gene-3 (LAG-3) receptors, which are involved in the activation of T-cells. The company used this knowledge to develop a platform of immunotherapeutics based on the stimulation of LAG-3 receptors, with the goal of enhancing the body's immune response against cancer and autoimmune diseases. Immutep's business model is based on the development and commercialization of immunotherapeutics that target LAG-3 receptors. The company focuses on the clinical development of therapeutics targeting various stages of cancer, such as lung cancer, prostate cancer, and breast cancer. Additionally, the company is also developing therapeutics for the treatment of autoimmune diseases such as multiple sclerosis, systemic lupus erythematosus, and Crohn's disease. Immutep is divided into various divisions to coordinate its activities in the areas of research and clinical development. These divisions include clinical development, research and development, and the production of immunotherapeutics. In the clinical development division, Immutep focuses on demonstrating the safety and efficacy of its immunotherapeutics in the treatment of cancer and autoimmune diseases. The company conducts clinical trials to evaluate the effectiveness of its therapeutics and obtain regulatory approval. Immutep's research and development department focuses on developing innovative immunotherapeutics based on LAG-3 receptors. The company has developed several patented technologies that enhance the effectiveness of the therapeutics and increase the body's tolerance to them. Immutep also operates a production division specializing in the manufacturing of immunotherapeutics. The company has production facilities in Europe and Asia, allowing it to distribute its therapeutics worldwide. The company offers a range of immunotherapeutics based on the stimulation of LAG-3 receptors. These therapeutics have been specifically developed for the treatment of cancer and autoimmune diseases and have the potential to enhance the body's immune response against these conditions. Immutep's products include IMP321, an immunotherapeutic specifically developed for the treatment of prostate cancer, and IMP701, an immunotherapeutic specifically developed for the treatment of lung cancer. Additionally, the company has several new therapeutics in clinical development, including IMP761 for the treatment of systemic lupus erythematosus and IMP731 for the treatment of Crohn's disease. Immutep is a leading company in the development of immunotherapeutics based on LAG-3 receptors. The company has a strong pipeline of therapeutics in clinical development and is well-positioned to benefit from the growing demand for immunotherapeutics for the treatment of cancer and autoimmune diseases. With its patented technologies and expertise in clinical development of immunotherapeutics, Immutep is well-equipped to grow and solidify its position as a leading company in this field. Immutep ist eines der beliebtesten Unternehmen auf Eulerpool.com.Liabilities Details
Assessing Immutep's Liabilities
Immutep's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immutep's financial stability, operational efficiency, and long-term viability.
Year-to-Year Comparison
By comparing Immutep's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.
Impact on Investments
Immutep's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.
Interpreting Liability Fluctuations
Shifts in Immutep’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.
Frequently Asked Questions about Immutep stock
What were the liabilities of Immutep compared to the previous year?
The liabilities of Immutep have increased by 35.68% increased compared to the previous year.
What are the consequences of high debt for investors of Immutep?
High liabilities can pose a risk for investors of Immutep, as they can weaken the company's financial position and impair its ability to meet its obligations.
What consequences do low liabilities have for investors in Immutep?
Low liabilities mean that Immutep has a strong financial position and is able to meet its obligations without overburdening its finances.
How does an increase in liabilities of Immutep affect the company?
An increase in liabilities of Immutep can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.
How does a reduction in the liabilities of Immutep affect the company?
A decrease in the liabilities of Immutep can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.
What are some factors that influence the liabilities of Immutep?
Some factors that can influence the liabilities of Immutep include investments, acquisitions, operating costs, and sales development.
Why is the level of liabilities of Immutep so important for investors?
The liabilities of Immutep are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.
What strategic measures can Immutep take to modify the liabilities?
To change its liabilities, Immutep can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.
How much dividend does Immutep pay?
Over the past 12 months, Immutep paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immutep is expected to pay a dividend of 0 AUD.
What is the dividend yield of Immutep?
The current dividend yield of Immutep is .
When does Immutep pay dividends?
Immutep pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Immutep?
Immutep paid dividends every year for the past 0 years.
What is the dividend of Immutep?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Immutep located?
Immutep is assigned to the 'Health' sector.
Wann musste ich die Aktien von Immutep kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Immutep from 8/26/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
When did Immutep pay the last dividend?
The last dividend was paid out on 8/26/2024.
What was the dividend of Immutep in the year 2023?
In the year 2023, Immutep distributed 0 AUD as dividends.
In which currency does Immutep pay out the dividend?
The dividends of Immutep are distributed in AUD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Immutep
Our stock analysis for Immutep Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Immutep Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
